Pfizer
New data for Pfizer arthritis pill
September 18, 2012Research and Development, Sales and Marketing JAK, Pfizer, RA, tofacitinib
Pfizer is to release more data for its investigational rheumatoid arthritis (RA) pill tofacitinib which it hopes will demonstrate its …
Pfizer and Hisun sign China generics deal
September 13, 2012Manufacturing and Production, Sales and Marketing China, Pfizer, branded generics, emerging markets, generics
Pfizer has unveiled a new joint venture with with China’s Zhejiang Hisun Pharmaceuticals. It is one of the first joint …
Ex-Pfizer head joins Red Door as International director
September 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Thomas, Pfizer, Red Door
Andrew Thomas the strategic communications lead for Pfizer’s primary care medicines across Europe and Canada joins Red Door Communications in …
Double approval for Pfizer cancer drugs
September 6, 2012Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc
Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …
Pfizer to develop phase II cancer vaccine
September 4, 2012Research and Development, Sales and Marketing Cancer, Pfizer, VLST, cancer vaccine
Pfizer has licensed a cancer compound which is ready for phase II study from a US firm specialising in cancer …
Pfizer and Mylan sign Japanese generics deal
August 23, 2012Sales and Marketing Mylan, Pfizer, generics
Pfizer and Mylan have struck a deal to sell generic drugs together in Japan, the world’s second biggest pharma market. …
Pfizer’s arthritis drug delayed by FDA
August 21, 2012Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib
Pfizer says its new rheumatoid arthritis drug tofacitinib has been delayed by the FDA. Tofacitinib, an oral Janus kinase (JAK) …
Claris LifeSciences gets clean bill of health from FDA
August 20, 2012Manufacturing and Production, Sales and Marketing Claris, FDA, Pfizer, sterile
Indian drugmaker Claris LifeSciences seems to have set its house in order after manufacturing issues led the FDA to impose …
Pfizer meets targets on greenhouse gases
August 16, 2012Manufacturing and Production GHGs, Merck, Pfizer
Pfizer says it has fulfilled its goal of cutting environmentally-harmful emissions from its facilities by 20%, a year ahead of …
Smoke and fire in J&J Code breach
August 15, 2012Sales and Marketing Champix, J&J, JJ, Johnson and Johnson, PMCPA, Pfizer
Johnson & Johnson has been censured for breaking the ABPI Code of Practice in printed information about its smoking cessation …
Pfizer pays $250m for OTC Nexium rights
August 14, 2012Sales and Marketing AstraZeneca, EMA, FDA, Nexium, OTC, Pfizer
Pfizer will pay $250 million to AstraZeneca in order to gain the rights to sell an over-the-counter form of the …
Pfizer signs drug profiling deal with Nodality
August 10, 2012Research and Development, Sales and Marketing Lupus, Nodality, Pfizer, SCNP
Pfizer has signed a multi-year drug profiling deal with Nodality to help get the best from its autoimmune disease compounds. …
Former Pfizer head Kindler joins Lux Capital
August 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kindler, Pfizer
Venture capital firm Lux Capital has appointed former Pfizer chairman and chief executive Jeff Kindler as a partner. Kindler will …
Pfizer pays $60m in bribery cases
August 8, 2012Sales and Marketing DoJ, FDA, GSK, Janssen, Pfizer, Wyeth, bribery
Pfizer has been fined $60 million for making improper payments to doctors in Europe, Asia and the Middle East. The …
Champix better than patches for smoking cessation
August 7, 2012Sales and Marketing Champix, FDA, Pfizer, Zyban, smoking
New research shows that Pfizer’s Champix is better than nicotine patch therapy at helping smokers kick the habit. A Pfizer …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
